Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$113.13

-1 (-0.88%)

06:39
11/29/16
11/29
06:39
11/29/16
06:39

Johnson & Johnson downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Geoff Meacham downgraded Johnson & Johnson to Equal Weight and lowered its price target to $125 from $130. The analyst said risk/reward is less compelling and said shares could become a source of funds due to Remicade biosimilar risk, slowing med tech utilization, reduced pipeline impact, and a move away from defensive names.

  • 29

    Nov

JNJ Johnson & Johnson
$113.13

-1 (-0.88%)

11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.

TODAY'S FREE FLY STORIES

10:50
02/27/17
02/27
10:50
02/27/17
10:50
General news
U.S. Dallas Fed manufacturing index rose 2.4 points to 24.5 in February »

U.S. Dallas Fed…

HBI

Hanesbrands

$20.60

-0.78 (-3.65%)

10:47
02/27/17
02/27
10:47
02/27/17
10:47
Technical Analysis
Hanesbrands drops, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

10:45
02/27/17
02/27
10:45
02/27/17
10:45
General news
Treasury Action: already elevated yields inched up further »

Treasury Action: already…

10:45
02/27/17
02/27
10:45
02/27/17
10:45
General news
Breaking General news story  »

Dallas Federal Reserve…

SPKE

Spark Energy

$27.25

1.7 (6.65%)

10:44
02/27/17
02/27
10:44
02/27/17
10:44
Recommendations
Spark Energy analyst commentary  »

Janney says Spark Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

10:44
02/27/17
02/27
10:44
02/27/17
10:44
General news
Dallas Fed Mfg Survey Production Index data reported »

February Dallas Fed Mfg…

UPS

UPS

$105.88

-0.3 (-0.28%)

10:41
02/27/17
02/27
10:41
02/27/17
10:41
Options
Opening action in UPS downside puts »

Opening action in UPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

10:37
02/27/17
02/27
10:37
02/27/17
10:37
General news
Dallas Fed Mfg Survey Production Index data reported »

February Dallas Fed Mfg…

TVPT

Travelport

$12.88

-0.06 (-0.46%)

10:33
02/27/17
02/27
10:33
02/27/17
10:33
Conference/Events
Travelport management to meet with Evercore ISI »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

PGNX

Progenics

$10.36

0.12 (1.17%)

10:32
02/27/17
02/27
10:32
02/27/17
10:32
Conference/Events
Progenics management to meet with Aegis »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 09

    Mar

ORIT

Oritani Financial

$17.15

-0.05 (-0.29%)

10:31
02/27/17
02/27
10:31
02/27/17
10:31
Conference/Events
Oritani Financial management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 02

    Mar

  • 15

    May

X

U.S. Steel

$37.37

0.355 (0.96%)

10:31
02/27/17
02/27
10:31
02/27/17
10:31
Options
Bullish short-term option play in US Steel as shares see strength »

Bullish short-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

10:30
02/27/17
02/27
10:30
02/27/17
10:30
Earnings
VimpelCom reports Q4 EBITDA $783M »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMS

Maximus

$60.41

0.1049 (0.17%)

10:30
02/27/17
02/27
10:30
02/27/17
10:30
Conference/Events
Maximus management to meet with Maxim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

10:29
02/27/17
02/27
10:29
02/27/17
10:29
General news
Market little changed in early trading as investors await Trump address »

Stock futures drifted…

CTSO

CytoSorbents

$5.60

0.05 (0.90%)

10:28
02/27/17
02/27
10:28
02/27/17
10:28
Conference/Events
CytoSorbents management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 03

    Mar

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

10:27
02/27/17
02/27
10:27
02/27/17
10:27
Hot Stocks
VimpelCom introduces new dividend policy »

VimpelCom introduces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$72.93

-0.42 (-0.57%)

10:26
02/27/17
02/27
10:26
02/27/17
10:26
Options
Colgate Palmolive call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BP

BP

$33.77

0.265 (0.79%)

10:25
02/27/17
02/27
10:25
02/27/17
10:25
Conference/Events
BP management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

10:25
02/27/17
02/27
10:25
02/27/17
10:25
General news
Treasury Action: yields remained above lows »

Treasury Action: yields…

BAH

Booz Allen

$36.13

0.205 (0.57%)

10:24
02/27/17
02/27
10:24
02/27/17
10:24
Conference/Events
Booz Allen management to meet with Drexel Hamilton »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

VCYT

Veracyte

$7.95

0.06 (0.76%)

10:23
02/27/17
02/27
10:23
02/27/17
10:23
Hot Stocks
Veracyte: Data show potential for non-invasive test to improve cancer diagnosis »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

AXP

American Express

$79.75

-0.01 (-0.01%)

, GOOG

Alphabet

$828.64

-2.69 (-0.32%)

10:23
02/27/17
02/27
10:23
02/27/17
10:23
Hot Stocks
American Express says doesn't have a 'deep' partnership with Google right now »

Says Marriott (MAR) has…

AXP

American Express

$79.75

-0.01 (-0.01%)

GOOG

Alphabet

$828.64

-2.69 (-0.32%)

MAR

Marriott

$87.08

0.08 (0.09%)

HOT

Starwood

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 19

    Mar

AAN

Aaron's

$27.23

0.05 (0.18%)

10:22
02/27/17
02/27
10:22
02/27/17
10:22
Conference/Events
Aaron's management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 01

    Mar

10:20
02/27/17
02/27
10:20
02/27/17
10:20
General news
FX Action: USD-CAD »

FX Action: USD-CAD traded…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.